DEM Biopharma aims to develop immunotherapies that will trigger macrophages and myeloid cells to eliminate tumors by recognizing “don’t eat me” (DEM) and “eat me” (EM) signals on cancer cells. Healthy cells have cell-surface proteins that provide DEM signals to tell macrophages to not destroy those cells. Cancer cells also present DEM signals to avoid destruction by macrophages. DEM Biopharma is using their proprietary CHoMP (Co-culture with Human Myeloid Phagocytes) platform to identify unknown DEM and EM signals. The platform utilizes inter-cellular CRISPR screening in co-cultures of tumor cells, macrophages, and other immune cells. By identifying novel DEM and EM signals, DEM Biopharma hopes to expand the therapeutic potential of DEM/EM targeting.

<p>DEM Biopharma aims to develop immunotherapies that will trigger macrophages and myeloid cells to eliminate tumors by recognizing “don’t eat me” (DEM) and “eat me” (EM) signals on cancer cells. Healthy cells have cell-surface proteins that provide DEM signals to tell macrophages to not destroy those cells. Cancer cells also present DEM signals to avoid destruction by macrophages. DEM Biopharma is using their proprietary CHoMP (Co-culture with Human Myeloid Phagocytes) platform to identify unknown DEM and EM signals. The platform utilizes inter-cellular CRISPR screening in co-cultures of tumor cells, macrophages, and other immune cells. By identifying novel DEM and EM signals, DEM Biopharma hopes to expand the therapeutic potential of DEM/EM targeting.</p>


DEM BioPharma

Business:

About:

Jobs:

News: